RT Journal Article
T1 Characterization of Conserved and Promiscuous Human Rhinovirus CD4 T Cell Epitopes
A1 Gómez Perosanz, Marta
A1 Fiyouzi Alipour, Tara
A1 Fernández Arquero, Miguel
A1 Sidney, John
A1 Sette, Alessandro
A1 Reinherz, Ellis L.
A1 Lafuente Duarte, María Esther
A1 Reche Gallardo, Pedro Antonio
AB Human rhinovirus (RV) is the most common cause of upper respiratory infections and exacerbations of asthma. In this work, we selected 14 peptides (6 from RV A and 8 from RV C) encompassing potential CD4 T cell epitopes. Peptides were selected for being highly conserved in RV A and C serotypes and predicted to bind to multiple human leukocyte antigen class II (HLA II) molecules. We found positive T cell recall responses by interferon gamma (IFNγ)-ELISPOT assays to eight peptides, validating seven of them (three from RV A and four from RV C) as CD4 T cell epitopes through intracellular cytokine staining assays. Additionally, we verified their promiscuous binding to multiple HLA II molecules by quantitative binding assays. According to their experimental HLA II binding profile, the combination of all these seven epitopes could be recognized by >95% of the world population. We actually determined IFNγ responses to a pool encompassing these CD4 T cell epitopes by intracellular cytokine staining, finding positive responses in 29 out of 30 donors. The CD4 T cell epitopes identified in this study could be key to monitor RV infections and to develop peptide-based vaccines against most RV A and C serotypes.
PB MDPI
SN 2073-4409
YR 2021
FD 2021-09-02
LK https://hdl.handle.net/20.500.14352/5046
UL https://hdl.handle.net/20.500.14352/5046
LA eng
NO Gomez- Perosanz, M., Fiyouzi Alipour, T., Fernández Arquero, M. et al. «Characterization of Conserved and Promiscuous Human Rhinovirus CD4 T Cell Epitopes». Cells, vol. 10, n.o 9, septiembre de 2021, p. 2294. DOI.org (Crossref), https://doi.org/10.3390/cells10092294.
NO This research was supported by UCM research special funds to P.A.R. and by the CAM research agency through grant IND2020/BMD-17364 to P.A.R.
NO Comunidad de Madrid
NO Universidad Complutense de Madrid
DS Docta Complutense
RD 4 abr 2025